Abstract: Gel compositions are provided that can be utilized as carriers for beneficial agents when injected into a subject and which can provide sustained release of the beneficial agent over time. In particular, gel compositions containing an agent that renders the composition thixotropic to facilitate injection of the gel into a subject with minimal discomfort to the subject are described.
Type:
Application
Filed:
September 19, 2013
Publication date:
April 24, 2014
Applicant:
DURECT CORPORATION
Inventors:
Guohua Chen, Paul Houston, Jeremy Corwin Wright, Jonas Fransson, Birger Hjertman
Abstract: An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having Cmax to Cmin ratio less than 200 and lag time less than 0.2.
Abstract: Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided.
Abstract: Polymeric devices for controlled release of an active agent of interest are provided. The active agent is provided within a biodegradable polymer system to supply a polymeric device for controlled release of the active agent. The polymer system is a copolymer or a polymer blend comprising a hydrophobic component and a hydrophilic component, and the polymer system does not form a hydrogel when contacted with, or immersed in an aqueous system, for example when the device is implanted in a subject. When the device is administered to a subject, for example, when it is implanted, the device releases the active agent in a controlled fashion without a lag period, or with a minimal lag period. Methods for producing the polymeric devices are also provided, as are methods of using the polymeric devices to provide for controlled release of an active agent in a subject.
Abstract: The present invention relates to novel nonpolymeric compounds and compositions that form liquid high viscosity materials suitable for the delivery of biologically active substances in a controlled fashion, and for use as medical or surgical devices. The materials can optionally be diluted with a solvent to form a material of lower viscosity, rendering the material easy to administer. This solvent may be water insoluble or water soluble, where the water soluble solvent rapidly diffuses or migrates away from the material in vivo, leaving a higher viscosity liquid material.
Abstract: Methods, including those for administering novel pharmaceutical compositions, dosage forms containing an opioid active pharmaceutical ingredient, are useful for treating pain, arthritic conditions and/or inflammation associated with a chronic condition, including pain from arthritis and inflammation.
Type:
Application
Filed:
October 22, 2012
Publication date:
November 28, 2013
Applicant:
Durect Corporation
Inventors:
Su Il Yum, Wendy Chao, Roger Fu, Michael Zamloot
Abstract: Injectable depot compositions with dual mechanisms of release rate control are provided for sustained beneficial agent delivery in a patient. The composition includes bioerodible particles and an injectable depot vehicle containing a bioerodible polymer in an organic solvent, for forming a bioerodible depot implant after administration to the patient. The bioerodible particles are dispersed in the depot vehicle and contain a beneficial agent and a release rate controlling agent retarding the release of the beneficial agent from the bioerodible particles and from the depot implant.
Type:
Application
Filed:
February 13, 2013
Publication date:
October 24, 2013
Applicant:
Durect Corporation
Inventors:
Guohua Chen, Paul R. Houston, Lothar W. Kleiner, Jeremy Corwin Wright
Abstract: The present invention is related to materials and methods for forming polymeric delivery vehicles that reduces risk of oxidative degradation of a carried drug and the resulting compositions.
Type:
Grant
Filed:
July 18, 2005
Date of Patent:
July 30, 2013
Assignee:
Durect Corporation
Inventors:
Pamela J. Fereira, Michael A. Desjardin, Catherine M. Rohloff, Stephen A. Berry, Ekaterina S. Zlatkova-Karaslavova
Abstract: A transdermal analgesic system having reduced potential for abuse, wherein the system provides for the controlled release of the antagonist at a rate sufficient to provide an abuse limiting release rate ratio of the antagonist to the analgesic when the dosage form is subject to abuse is disclosed.
Type:
Grant
Filed:
April 22, 2003
Date of Patent:
May 14, 2013
Assignee:
Durect Corporation
Inventors:
Robert M. Gale, Thomas M. Stein, Jay Audett, Jane Stepic, Joseph B. Phipps, Michel J. N. Cormier
Abstract: Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.
Type:
Grant
Filed:
February 3, 2012
Date of Patent:
April 16, 2013
Assignee:
Durect Corporation
Inventors:
Su Il Yum, Grant Schoenhard, Arthur J. Tipton, John W. Gibson, John C. Middleton
Abstract: Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.
Type:
Grant
Filed:
February 3, 2012
Date of Patent:
January 15, 2013
Assignee:
Durect Corporation
Inventors:
Su Il Yum, Grant Schoenhard, Arthur J. Tipton, John W. Gibson, John C. Middleton
Abstract: Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, depot gel compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a short duration of time. The compositions include a low molecular weight biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.
Abstract: A coaxial implant has been developed using entirely biodegradable polymeric materials. As referred to herein, a coaxial implant is a device having a core containing drug, surrounded by a semi-permeable membrane that controls the rate of release of material from the core. The device is formed by extrusion, using a pre-milling and extruding step to maximize uniformity of drug dispersion within the polymeric material. In one embodiment, the polymer is processed to yield a semi-crystalline polymer, rather than an amorphous polymer. The core containing the drug and the polymer membrane(s) can be the same or different polymer. The polymer can be the same or different composition (i.e., both polycaprolactone, or both poly(lactide-co-glycolide) of different monomer ratios, or polycaprolactone outside of a core of poly(lactide)), of the same or different molecular weights, and of the same or different chemical structure (i.e., crystalline, semi-crystalline or amorphous).
Type:
Grant
Filed:
June 21, 2002
Date of Patent:
September 11, 2012
Assignee:
Durect Corporation
Inventors:
John W. Gibson, Arthur J. Tipton, Richard J. Holl, Stacey Meador
Abstract: Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided.
Abstract: Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided.